CLINICAL_TRIALS
trial_result
· 2026-01-21
Clinical Trial Update: An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM [Phase 3]
Summary
An open-label Phase 3 trial of aficamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Corxel Pharmaceuticals | Conditions: Obstructive Hypertrophic Cardiomyopathy | Phase 3 | Status: COMPLETED